Autifony Therapeutics
Recent Finacing
Equity
Recent Raise
$1.6M
Autifony Therapeutics develops Kv3 potassium‑channel modulators for hearing disorders (tinnitus, age‑related hearing loss, cochlear‑implant studies) and other CNS indications, advancing clinical-stage programs including AUT00063 and AUT00206.
Highlights
Focus Areas
Biotechnology
Medical Device
Therapeutics
Recent Investors
Financials
$17.7M
Total Raised
3
Funding rounds
7
Investors